Neurocrine Biosciences

Latest news

• Neurocrine Biosciences (NASDAQ:NBIX): Affordable Growth at a Reasonable Valuation (opens in a new tab)

  ChartMill · Oct 2, 2026

• Neurocrine advances research on VYKAT XR for Pr... (opens in a new tab)

  Pluang · Sep 30, 2026

• Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference (opens in a new tab)

  PR Newswire · Sep 30, 2026

• Learn Why The Bull Case For Neurocrine Biosciences Stock Could Change Following CMO Return (opens in a new tab)

  Simply Wall Street · Sep 30, 2026

• Neurocrine Biosciences selects Ruder Finn as communications AOR (opens in a new tab)

  Medical Marketing and Media · Sep 29, 2026

• UBS cuts Neurocrine Biosciences stock price target to $214 on competition (opens in a new tab)

  Investing.com · Sep 29, 2026

• ETFs Investing in Neurocrine Biosciences, Inc. Stocks (opens in a new tab)

  TradingView · Sep 29, 2026

• Ruder Finn Wins Neurocrine Biosciences US AOR (opens in a new tab)

  PRovoke Media · Sep 29, 2026

• Neurocrine Biosciences (NBIX) Could Be 34% Undervalued After Its CMO Return (opens in a new tab)

  Simply Wall Street · Sep 29, 2026

• Neurocrine Biosciences names Eiry Roberts as chief medical officer (opens in a new tab)

  Investing.com · Sep 28, 2026

• Neurocrine Biosciences Names Eiry Roberts Chief Medical Officer (opens in a new tab)

  marketscreener.com · Sep 28, 2026

• Neurocrine names Eiry Roberts chief medical officer (opens in a new tab)

  Stock Titan · Sep 28, 2026

• Neurocrine Biosciences, Inc. Announces Chief Medical Officer Changes (opens in a new tab)

  marketscreener.com · Sep 28, 2026

• Neurocrine Biosciences names Eiry W. Roberts as Chief Medical Officer, replacing Sanjay Keswani. (opens in a new tab)

  Pluang · Sep 28, 2026

• Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer (opens in a new tab)

  PR Newswire · Sep 28, 2026

• Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last? (opens in a new tab)

  Eastern Progress · Sep 23, 2026

• Neurocrine’s (NBIX) Data Deluge Reshapes A Familiar Growth Story (opens in a new tab)

  Yahoo Finance · Sep 17, 2026

• Neurocrine Biosciences' CCO Eric Benevich Reports Share Award and Forfeiture on September 11, 2026 (opens in a new tab)

  Kalkine Media · Sep 16, 2026

• Neurocrine Biosciences chief corp. affairs officer David Boyer sells $130k in stock (opens in a new tab)

  Investing.com · Sep 16, 2026

• CFO at Neurocrine Biosciences (NBIX) sells shares after performance award vests (opens in a new tab)

  Stock Titan · Sep 15, 2026

• Neurocrine Biosciences (NBIX) CMO reports stock vesting, no market sale (opens in a new tab)

  Stock Titan · Sep 15, 2026

• PRSU vest gives Neurocrine Biosciences (NBIX) officer 3,587 shares (opens in a new tab)

  Stock Titan · Sep 15, 2026

• Neurocrine (NASDAQ: NBIX) officer plans $736K stock sale (opens in a new tab)

  Stock Titan · Sep 14, 2026

• Neurocrine Biosciences at Wells Fargo conference: growth story broadens (opens in a new tab)

  Investing.com · Sep 9, 2026

• Neurocrine Biosciences' Ingrezza, Crenessity to Drive H2 Ahead of 'Catalyst-Rich' 2027, RBC Says (opens in a new tab)

  Yahoo Finance · Sep 8, 2026

• Neurocrine Biosciences (NBIX) Stock Could Still Be A Bargain After A 61% Run (opens in a new tab)

  Simply Wall Street · Sep 6, 2026